1. Scrip
  2. >>Conferences
  3. >>ASCO

Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO

“Practice Changing” KEYNOTE-564 Data Presented At ASCO Plenary

 
• By Alaric DeArment

The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.

Human kidney on scientific background. 3d illustration
Merck & Co. presents "practice changing" data on Keytruda in adjuvant renal cell carcinoma • Source: Shutterstock

The KEYNOTE-564 study supporting use of Merck & Co., Inc.’s Keytruda(pembrolizumab) in adjuvant renal cell carcinoma (RCC), and likely another first-to-market advantage for the PD-1 inhibitor, is an important advance as checkpoint inhibitor immuno-oncology shifts to earlier use in adjuvant settings in various cancers.

The Kenilworth, NJ-based drug maker presented positive data from the Phase III KEYNOTE-564 study comparing Keytruda with placebo in adjuvant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences

MFN And Confidential Pricing: What Experts Said

 
• By Anju Ghangurde

Experts at a recent summit discussed the complexities and impact of US MFN pricing from a payer perspective and emphasized the importance of a centralized purchaser of drugs to effectively negotiate prices. The potential rise of 'confidential discounts' in Germany was another key talking point.

How Korean Biotech Can Overcome Investment, Regulatory Hurdles

 
• By Jung Won Shin

At recent conferences in Seoul, participants discussed various hurdles for growth in the Korean biotech ecosystem and potential opportunities such as the ongoing collaborations between Korea and Japan.

ESMO 25: What Was Behind Bemarituzumab’s Waning Efficacy In FORTITUDE-101?

 
• By Alexandra Shimmings

While Amgen and Zai Labs await the results of a second Phase III trial before filing for approval, some hints as to what might have gone wrong for their FGFR2b-targeting monoclonal antibody in FORTITUDE-101 came with the full data presentation at ESMO this week.